Search Results

Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble

Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and further erode confidence that the biotech can effectively mitigate the impacts of Jakafi’s loss of exclusivity in the coming years, according to analysts.

November 19, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Incyte to Present at Upcoming Investor Conference

November 14, 2024

·

1 min read

Approvals

Incyte Wins Second Graft-Versus-Host Disease FDA Approval

Nearly two weeks ahead of its target action date, the regulator on Wednesday has signed off on Incyte and Syndax’s Niktimvo for the third-line treatment of graft-versus-host disease.

August 15, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Incyte to Present at Upcoming Investor Conferences

October 30, 2024

·

1 min read

Pipeline

Incyte Trims Early-Stage Pipeline Amid Strategic Shift in R&D

Incyte announced Tuesday it is realigning its research and development priorities to focus on dermatology and inflammatory assets obtained from the $750 million acquisition of Escient Pharmaceuticals.

July 31, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

November 19, 2024

·

2 min read

Deals

Incyte Completes Acquisition of Escient Pharmaceuticals

Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders.

May 30, 2024

·

5 min read

Press Releases

Incyte to Report Third Quarter Financial Results

October 8, 2024

·

1 min read

BioCapital

Incyte to Present at Upcoming Investor Conference - May 21, 2024

Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45 th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) in Miami.

May 21, 2024

·

1 min read

Press Releases

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

September 26, 2024

·

6 min read